Literature DB >> 10483524

The kinetics of elastolysis: elastin catabolism during experimentally induced fibrosis.

B Starcher1, B Peterson.   

Abstract

Lung injury and matrix destruction result in the release into the circulation of desmosine, a product of elastin catabolism. To determine whether measurements of desmosine concentrations in the urine can provide important information about the severity of lung injury, we measured the kinetics of lung elastin catabolism following elastase-induced and fibrotic lung injury in mice. Pancreatic elastase instillation in the lung caused immediate elastin destruction, removing as much as 25% of the lung elastin within the first few hours. Peak concentrations of desmosine peptides appeared in the blood within 1-2 hours, and soluble elastin peptides in the lung and urine followed a similar course with peak levels occurring early and then declining rapidly, approaching control levels by 24 hours. More than half of the desmosine peptides removed from the lung following elastase injury were sequestered by the kidney and then slowly released over a period of several days. Lung histology and morphological measurements indicated that bleomycin, TiO2, and SiO2 instillation resulted in severely fibrotic lungs. However, the lung injuries sustained from these agents resulted in minimal elastin damage, representing less than 0.1% of the total lung elastin catabolized as estimated by desmosine analysis. The rapid accumulation of desmosine in renal tissue and its slow release into the urine keep urine concentrations low and minimize the power of urine desmosine assays for quantifying low level tissue destruction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10483524     DOI: 10.1080/019021499270169

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  4 in total

1.  The utility of urine desmosine as a marker of lung injury in spine surgery.

Authors:  Stavros G Memtsoudis; Barry Starcher; Yan Ma; Valeria Buschiazzo; Michael K Urban; Federico P Girardi
Journal:  HSS J       Date:  2010-03-10

2.  Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.

Authors:  Theresa A Laguna; Brandie D Wagner; Heidi K Luckey; Shelley A Mann; Scott D Sagel; Warren Regelmann; Frank J Accurso
Journal:  Chest       Date:  2009-06-30       Impact factor: 9.410

3.  Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease.

Authors:  Jeffrey T J Huang; Rekha Chaudhuri; Osama Albarbarawi; Alun Barton; Christal Grierson; Petra Rauchhaus; Christopher J Weir; Martina Messow; Nicola Stevens; Charles McSharry; Giora Feuerstein; Somnath Mukhopadhyay; Jeffrey Brady; Colin N A Palmer; Douglas Miller; Neil C Thomson
Journal:  Thorax       Date:  2012-01-16       Impact factor: 9.139

4.  Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency.

Authors:  Jan Stolk; Barbara Veldhuisen; Laura Annovazzi; Chiara Zanone; Elly M Versteeg; Toine H van Kuppevelt; Jo H M Berden; Willem Nieuwenhuizen; Paolo Iadarola; Maurizio Luisetti
Journal:  Respir Res       Date:  2005-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.